A single-center, single-dose, randomized, three-way crossover phase I study comparing pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC, with Buccal Sativex in healthy volunteers

Trial Profile

A single-center, single-dose, randomized, three-way crossover phase I study comparing pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC, with Buccal Sativex in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Nabiximols
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Aug 2017 Results published in an Intec Pharma media release.
    • 22 Mar 2017 According to an Intec Pharma media release, topline results from this trial are expected in the third quarter of 2017.
    • 22 Mar 2017 Status changed from planning to recruiting, as reported in an Intec Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top